Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 1 February 2005, Vol. 105, No. 3, pp. 917.

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ossenkoppele, G.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Ossenkoppele, G.
Related Collections
Right arrowRelated Article in Blood Online
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow


InsideBlood

NEOPLASIA

Comment on Guo et al, page 1246

Is hsp70 another target for Ph+ leukemias?

Gert Ossenkoppele

VU UNIVERSITY MEDICAL CENTER, AMSTERDAM

In this manuscript, Guo and colleagues describe a mechanistic role for heat shock protein 70 in Bcr-Abl–mediated resistance in leukemia cells, suggesting another promising therapeutic target for reversing drug resistance in Ph+ leukemias.

The bcr-abl oncogene generated by the t(9;22) is one of the most highly studied oncogenes. It is regarded as the hallmark for chronic myeloid leukemia (CML). The constitutive kinase activity of the bcr-abl fusion gene leads, via a myriad of signal transduction pathways, to enhanced proliferation, genomic instability, and cytoskeletal abnormalities and to decreased apoptosis. Although several molecular mechanisms resulting in the antiapoptosis properties of Bcr-Abl have been unraveled, there are still many gaps in our knowledge. Bcr-Abl expression results in resistance to apoptosis by cytostatic drugs but also inhibits the extrinsic pathway of apoptosis. In this issue of Blood, Guo and colleagues attempted to elucidate the role of heat shock protein 70 (hsp70) in Bcr-Abl–mediated antiapoptotic pathways in human leukemic cells. It was shown that Bcr-Abl expression (ectopic or endogenous) in leukemic cells results in the up-regulation of the antiapoptotic hsp70 leading to induction and activation of signal transducers and activators of transcription 5 (STAT5) and interference with several apoptosis signaling pathways at multiple levels (see figure). Attenuation of hsp70 levels either by imatinib or hsp70 antisense sensitized K562 cells to cytarabine (Ara-C), etoposide, and also Apo-2 ligand (Apo-2L)/tumor necrosis factor (TNF)–related apoptosis-inducing ligand (Apo-2L/TRAIL)–induced apoptosis. Higher levels of phosphorylated heat shock factor-1 (pHSF-1) were found in bcr-abl–positive cell lines, suggesting a regulatory role for HSF-1 in hsp70 expression. Imatinib down-regulated pHSF-1 and hsp70 expression in bcr-abl–positive leukemic cells. Remarkably, the death-inducing signaling complex (DISC), as well as apoptosis, was inhibited by hsp70. From these elegantly performed studies, the overall important conclusion can be drawn that hsp70 plays a central role in both the extrinsic and intrinsic apoptotic signaling of bcr-abl–positive leukemic cells, STAT5 dependent and independent. Most of the results were obtained in cell lines; just overexpression of hsp70 and hsp90 was shown in primary cells derived from blast crisis patients. It would be of interest to see whether these observations also apply for the CD34+ leukemic cells in chronic phase of CML or if the up-regulation of hsp70 is just restricted to later phases of the disease.Go



Infection with dominant negative (DN) STAT 5 sensitizes HL-60/hsp70 cells to Ara-C and etoposide-induced cell death. See the complete figure in the article beginning on page 1246.

 

The successful treatment of CML with the "Bcr-Abl–specific" tyrosine kinase inhibitor imatinib leading to complete cytogenetic remissions in a high percentage of patients if applied in chronic phase has transformed this disease into a paradigm for targeted therapy.

However, primary or secondary resistance is not an infrequent event and although complete remissions can also be achieved in advanced stage CML, mostly, these are unsustained. Therefore, the search for other drugs, effectively targeting perturbed signal transduction pathways involved in the pathogenesis of CML, is warranted. Switching off not only Bcr-Abl but also other key proteins could potentially overcome primary as well as secondary resistance. Various new small molecules are currently being tested either in vitro or in vivo. Hsp70 could be a suitable target for these and, it is hoped, become the Achilles heel of the leukemic cell. {blacksquare}


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Article in Blood Online:

Mechanistic role of heat shock protein 70 in Bcr-Abl–mediated resistance to apoptosis in human acute leukemia cells
Fei Guo, Celia Sigua, Purva Bali, Prince George, Warren Fiskus, Anna Scuto, Srinivas Annavarapu, Abdelmoughite Mouttaki, Gautam Sondarva, Sheng Wei, Jie Wu, Julie Djeu, and Kapil Bhalla
Blood 2005 105: 1246-1255. [Abstract] [Full Text] [PDF]




This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ossenkoppele, G.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Ossenkoppele, G.
Related Collections
Right arrowRelated Article in Blood Online
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020